SAN Sanofi

   By Donato Paolo Mancini 
 

Sanofi SA (SAN.FR) said Thursday that its fourth-quarter sales and business net income grew.

Business net income, an important adjusted metric for the company, grew 4.3% to 1.4 billion euros ($1.6 billion) in the fourth quarter, the company said. Business EPS in the period was EUR1.10, up 4.7%. In 2018, adjusted profit for the company was EUR6.8 billion, while 2018 business EPS was EUR5.47.

Sales in the fourth quarter grew 3.9% to EUR9 billion, while they declined to EUR34.46 billion for the full year, from EUR35.01 billion in 2017.

Excluding Animal Health gains on disposal, full-year IFRS net income was up 14.5% and full-year IFRS EPS was up 15.3%, the company said.

Sanofi said for 2019 it expects adjusted business EPS to grow between 3% and 5%, and said it delivered adjusted business EPS at the high end of its old guidance range.

Sanofi was expected to post 2018 sales of EUR35.1 billion, and adjusted business EPS of EUR5.47, according to a consensus estimate compiled by FactSet.

Full-year sales of its rare-blood disorder franchise were EUR897 million, Sanofi said. It had a number of important drug approvals, including Cablivi, in Europe and the U.S.

"In 2018, we executed on important launches including Dupixent, Libtayo, and Cablivi, as the headwinds from our U.S. [diabetes losses of exclusivity] began to moderate," said Chief Executive Olivier Brandicourt. "Additionally, the acquisitions of Bioverativ and Ablynx provided the foundation to build a leading Rare Blood Disorder franchise and to enhance our biologic discovery capabilities," he said.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini

(END) Dow Jones Newswires

February 07, 2019 01:46 ET (06:46 GMT)

Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024